NEWS & Topics

2023.01.27 FDA has granted Fast Track Designation to Tamibarotene for the treatment of higher risk MDS.
2022.08.04 EMA committee issued Positive Opinion to TM-411 for MDS on Orphan Drug Designation.
2022.07.11 Approval of use patent for TM-411 as a cancer stem cell proliferation inhibitor by European Patent Office.
Focusing on cancer!
Business areas

Company Overview